Literature DB >> 20887132

Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.

Jackson A Gondim1, João Paulo Almeida, Lucas Alverne F de Albuquerque, Erika Gomes, Michele Schops, Tania Ferraz.   

Abstract

OBJECT: Acromegaly is a chronic disease related to the excess of growth hormone (GH) and insulin-like growth factor–I secretion, usually by pituitary adenomas. Traditional treatment of acromegaly consists of surgery, drug therapy, and eventually radiotherapy. The introduction of endoscopy as an additional tool for surgical treatment of pituitary adenomas and, therefore, acromegaly represents an important advance of pituitary surgery in the recent years. The aim of this retrospective study is to evaluate the results of pure transsphenoidal endoscopic surgery in a series of patients with acromegaly who were operated on by a pituitary specialist surgeon. The authors discuss the advantages, outcome, complications, and factors related to the success of the endoscopic approach in cases of GHsecreting adenomas.
METHODS: The authors retrospectively analyzed data from cases involving patients with GH-secreting adenomas who underwent pure transsphenoidal endoscopic surgery at the Department of Neurosurgery of the General Hospital in Fortaleza, Brazil, between 2000 and 2009. Tumors were classified according to size as micro- or macroadenomas, and tumor extension was analyzed based on suprasellar/parasellar extension and sella floor destruction. All patients were followed up for at least 1 year. The criteria of disease control were GH levels < 1 ng/L after oral glucose tolerance test and normal insulin-like growth factor–I levels for age and sex.
RESULTS: During the study period, 67 patients underwent pure endoscopic transsphenoidal surgery for treatment of acromegaly. Disease control was obtained in 50 cases (74.6%). The rate of treatment success was higher in patients with microadenomas (disease control achieved in 12 [85.7%] of 14 cases) than in those with larger lesions. Suprasellar/parasellar extension and high levels of sella floor erosion were associated with lower rates of disease control (p = 0.01 and p = 0.02, respectively). Complications related to the endoscopic surgery included epistaxis (6.0%), transitory diabetes insipidus (4.5%), and 1 case of seizure (1.5%).
CONCLUSIONS: Endoscopic transsphenoidal surgery represents an effective option for treatment of patients with acromegaly. High disease control rates and a small number of complications are some of the most important points related to the technique. Factors related to the success of the endoscopic surgery are lesion size, suprasellar/parasellar extension, and the degree of sella floor erosion. Although presenting important advantages, there is no conclusive evidence that endoscopy is superior to microsurgery in treatment of GH-secreting adenomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20887132     DOI: 10.3171/2010.7.FOCUS10167

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  25 in total

1.  Immediate and delayed postoperative morbidity in functional and non-functioning pituitary adenomas.

Authors:  Anna Aulinas; Cristina Colom; Juan Ybarra; Fernando Muñoz; Pere Tresserras; Eugenia Resmini; Susan M Webb
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

2.  Endoscopic versus microscopic approach for surgical treatment of acromegaly.

Authors:  Hussein Fathalla; Michael D Cusimano; Antonio Di Ieva; John Lee; Omar Alsharif; Jeannette Goguen; Stanley Zhang; Harley Smyth
Journal:  Neurosurg Rev       Date:  2015-02-10       Impact factor: 3.042

3.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

4.  Random Gh and Igf-I levels after transsphenoidal surgery for acromegaly: relation with long-term remission.

Authors:  Marcelo Lemos Vieira da Cunha; Luis Alencar Biurrum Borba; Cesar Luiz Boguszewski
Journal:  Endocrine       Date:  2020-02-20       Impact factor: 3.633

5.  Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.

Authors:  Susanna Bacigaluppi; Federico Gatto; Pasquale Anania; Nicola Luigi Bragazzi; Diego Criminelli Rossi; Giulia Benvegnu; Elena Nazzari; Renato Spaziante; Massimo Giusti; Diego Ferone; Gianluigi Zona
Journal:  Endocrine       Date:  2015-05-17       Impact factor: 3.633

6.  Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission.

Authors:  Samuel S Shin; Matthew J Tormenti; Alessandro Paluzzi; William E Rothfus; Yue-Fang Chang; Hanady Zainah; Juan C Fernandez-Miranda; Carl H Snyderman; Sue M Challinor; Paul A Gardner
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

7.  Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications.

Authors:  Thomas J Wilson; Erin L McKean; Ariel L Barkan; William F Chandler; Stephen E Sullivan
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

Review 8.  The surgical treatment of acromegaly.

Authors:  Michael Buchfelder; Sven-Martin Schlaffer
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

9.  Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases.

Authors:  Adam N Mamelak; John Carmichael; Vivien H Bonert; Odelia Cooper; Shlomo Melmed
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

10.  The impact of endoscopic transsphenoidal pituitary adenoma surgery on endocrine function: a single-centre study.

Authors:  Luke Galloway; Mohamed Ali; Andrew Lansdown; Peter Taylor; Aled Rees; John Stephen Davies; Caroline Hayhurst
Journal:  Acta Neurochir (Wien)       Date:  2020-10-21       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.